Frovatriptan: A selective type 1B/1D serotonin receptor agonist for the treatment of migraine headache

Drugs of Today

Volumn 38, Issue 9, 2002, Pages 615-629

  Cole, Patrick ^a   Rabasseda, Xavier ^a  

^a Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; ACETYLSALICYLIC ACID; ANALGESIC AGENT; BRL 54443; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROERGOTAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; ERGOT ALKALOID; ERGOTAMINE; FLUVOXAMINE; FROVATRIPTAN; HISTAMINE H3 RECEPTOR AGONIST; MOCLOBEMIDE; N [4 [5 [3 (2 AMINOETHYL) 1H INDOL 5 YL] 1,2,4 OXADIAZOL 3 YL]BENZYL]METHANESULFONAMIDE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROPRANOLOL; RIZATRIPTAN; SEROTONIN; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D AGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN 1F AGONIST; SEROTONIN 1F RECEPTOR; SEROTONIN AGONIST; SUMATRIPTAN; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOCONSTRICTOR AGENT; ZOLMITRIPTAN;

ARTERY CONSTRICTION; CLINICAL TRIAL; CLUSTER HEADACHE; CORONARY ARTERY DISEASE; DISORIENTATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; MENINGEAL ARTERY; MIGRAINE; NAUSEA; NONHUMAN; REVIEW; TENSION HEADACHE; THORAX PAIN;

ADULT; AGED; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBAZOLES; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTAMINES;

EID: 0036751801     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2002.38.9.696537     Document Type: Review

References (36)

1. Sumatriptan succinate. Drugs of Today 1992, 28: 1550-9.
2. Rabasseda, X., Hopkins, S.J. Update on sumatriptan subcutaneous injection for the relief of migraine headache. Drugs of Today 1994, 30: 411-34.
3. Rabasseda, X. Almotriptan in the treatment of migraine, XR manuscript. Drugs of Today 2001; 37: 5-12.
4. Graul, A. et al. SB-209509/VML-251. Drugs of the Future 1997, 22: 725.
5. Parsons, A. et al. Effects of the novel antimigraine agent, frovatriptan, on coronary and cardiac function in dogs. J Cardiovasc Pharmacol 1998, 32: 995.
6. Frovatriptan. Drugs of the Future 1999, 24: 801.
7. Brown, A. et al. SB 209509 (VML 251), a potent constrictor of rabbit basilar artery with high affinity and selectivity for human 5-HT1D receptors. Br J Pharmacol 1996, 119(Suppl.): Abst 110P.
8. Raval, P. et al. A comparison of the agonist profile of SB 209509 (VML 251) and sumatriptan in human isolated basilar and coronary arteries. Br J Pharmacol 1996, 119(Suppl.): Abst 111P.
9. Parsons, A. et al. Effects of the novel high-affinity 5-HT1B/1D-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol 1998, 32: 220.
10. Parsons, A. et al. Comparison of the cardiovascular effects of SB 209509 (VML 251) and sumatriptan in dogs. Br J Pharmacol 1996, 119 (Suppl.): Abst 109P.
11. Parsons, A. et al. Comparison of the cardiovascular effects of the novel 5-HT1B/1D receptor agonist, SB 209509 (VML251), and sumatriptan in dogs. J Cardiovasc Pharmacol 1997, 30: 136.
12. Xu. Y. et al. N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist. J Med Chem 1999, 42: 526.
13. McHarg, A. et al. The functional activity of eletriptan and other 5-HT1B/1D agonists at the human recombinant 5-HT1B and 5-HT1D receptors. Headache 1999, 39: 369.
14. Stewart, M. et al. The binding affinity and functional activity of eletriptan and other 5-HT 1B/1D agonists at the human recombinant 5-HT1B and 5-HT1D receptors. Br J Pharmacol 1999, 127(Suppl.): Abst 93P.
15. Buchan,P. et al. Pharmacokinetics of frovatriptan (VML 251/SB 209509) in healthy young and elderly male and female subjects. 12th Migraine Trust Symp 1998: Abst P.52.
16. Buchan, P. et al. Pharmacokinetics of frovatriptan (VML 251/SB 209509) in male and female subjects. Eur J Neurol 1998, 5 (Suppl. 3): S58.
17. Buchan, P. et al. Pharmacokinetics of frovatriptan in young and elderly subjects. Headache 1999, 39: 346.
18. Buchan, P. The pharmacokinetics of frovatriptan (VML 251/SB 209509), a potent selective 5-HT1B/1D agonist, following single dose administration by oral and intravenous routes to healthy male and female volunteers. 40th Annu Sci Meet AM Assoc Study Headache 1998: Abst. 63.
19. Buchan, P. et al. Lack of clinically significant interactions between frovatriptan and ergotamine. Cephalalgia 1999, 19: Abst II-G1-31.
20. Buchan, P. et al. Lack of interaction between frovatriptan and monoamine oxidase inhibitor moclobemide. Cephalalgia 1999, 19: Abst IIG1-30.
21. Spierings, E. et al. Consistent migraine relief with frovatriptan, a novel 5HT1B/1D agonist. Cephalalgia 1999, 19: Abst II-G1-40.
22. Rapoport, A., Keywood, C. Frovatriptan - Dose response studies. Headache 1999, 39: 375.
23. Goldstein, J. et al. A low-dose range-finding study of frovatriptan: A potent selective 5-HT1B/1D agonist for the acute treatment of migraine. 40th Annu Sci Meet Am Assoc Study Headache 1998: Abst. 159.
24. Goldstein, J. et al., Low 24-hour migraine recurrence during treatment with frovatriptan. Cephalalgia 1999, 19: Abst II-G1-36.
25. McDaris, H. et al. Frovatriptan - A review of overall. Cephalalgia 1999, 19: Abst II-G1-41.
26. Spierings, E. et al. Frovatriptan - A review of safety and tolerability. Cephalalgia, 1999, 19: Abst II-GI-41.
27. MacGregor, E.A., Keywood, C. Frovatriptan is effective menstrually associated migraine. Cephalalgia 2000, 20: Abst. 196.
28. MacGregor, E.A., Spierings, E. Frovatriptan consistently provides rapid and complete migraine relief in long-term treatment. Cephalalgia 2000, 20: Abst. 195.
29. Spierings, E.L.H., Keywood, C. Clinical factors associated with low headache recurrence with frovatriptan. Cephalgia 2000, 20: Abst 183.
30. Geraud, G., Keywood, C. Tolerability of frovatriptan during short and long-term use for acute migraine and in comparison with sumatriptan. Cephalalgia 2000, 20: Abst. 225.
31. Keywood, C., Wetherill, G., Sugden, P. Frovatriptan broad therapeutic index: Relationship of adverse events occurrence to frovatriptan blood levels. Cephalalgia 2001, 21: Abst P1-H23.
32. 7 receptors. Cephalalgia 2001, 21: Abst P1-H28.
33. Geraud, G. Migraine headache recurrence: Relationship to clinical, pharmacological and pharmacokinetic properties of triptans. Cephalalgia 2001, 21: Abst P2-K4.
34. Cady, R., Keywood, C. Frovatriptan: Preliminary efficacy in the early treatment of migraine attacks. Cephalalgia 2001, 21: Abst P2-K48.
35. Wade, A., Buchan, P., Mant, T., Ward, C. Frovatriptan has no clinically significant interaction with fluvoxamine. Cephalalgia 2001, 21: Abst P2-K49.
36. Goldstein, J., Keywood, C. Frovatriptan for the acute treatment of migraine: A dose-finding study. Headache 2002, 42: 41-8.